Gossamer Bio Under Investigation as Stock Plummets 80%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Gossamer Bio, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to significant legal risks.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, directly impacting investor confidence and raising concerns about the company's drug pipeline.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting extreme market pessimism regarding the company's future prospects and financial health.
- Potential Legal Consequences: The investigation could lead to a class action lawsuit against Gossamer, and if found guilty of fraud, the company may face severe financial repercussions and reputational damage, prompting investors to closely monitor developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.373
Low
10.00
Averages
12.33
High
15.00
Current: 0.373
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Under Investigation as Stock Plummets 80%
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Gossamer Bio, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to significant legal risks.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, directly impacting investor confidence and raising concerns about the company's drug pipeline.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting extreme market pessimism regarding the company's future prospects and financial health.
- Potential Legal Consequences: The investigation could lead to a class action lawsuit against Gossamer, and if found guilty of fraud, the company may face severe financial repercussions and reputational damage, prompting investors to closely monitor developments.
See More
Cantor Fitzgerald Downgrades Gossamer Bio Amid Regulatory Uncertainty
- Rating Downgrade: Cantor Fitzgerald has downgraded Gossamer Bio from overweight to neutral due to uncertainty surrounding the regulatory path for seralutinib as a treatment for pulmonary arterial hypertension, indicating a decline in market confidence regarding the drug's future prospects.
- Clinical Trial Disappointment: The topline results from the February PROSERA phase 3 study failed to meet statistical significance, leading analysts to adopt a cautious stance on Gossamer's commercialization potential, although they still acknowledge some compelling data indicating a solid signal for the drug.
- FDA Meeting Request: Gossamer has requested a Type C meeting with the US FDA, expected to take place in June, which should provide clearer guidance on seralutinib's path forward, with potential clarity anticipated in July.
- Market Sentiment: Analyst Olivia Brayer Saunders noted that while Gossamer possesses some compelling data, the lack of strong conviction regarding the commercialization path may impact investor sentiment towards the company's long-term outlook.
See More
Gossamer Bio Under Investigation as Stock Plummets 80.14%
- Investigation Launched: Pomerantz LLP is investigating Gossamer Bio, Inc. for potential securities fraud or unlawful business practices, highlighting serious concerns among investors regarding corporate governance.
- Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, leading to a significant drop in market confidence.
- Stock Plunge: Following the trial failure announcement, Gossamer's stock price fell by $1.71, a staggering 80.14% decline, closing at $0.423 per share, reflecting investors' pessimism about the company's future prospects.
- Legal Implications: The investigation may result in Gossamer facing class action lawsuits, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, further exacerbating the legal risks the company faces.
See More
Gossamer Bio Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Report: Gossamer Bio's Q4 GAAP EPS of -$0.21 missed expectations by $0.02, indicating ongoing challenges in achieving profitability despite revenue growth.
- Revenue Surge: The company reported Q4 revenue of $13.8 million, a 47.8% year-over-year increase, exceeding market expectations by $6.28 million, reflecting strong product demand and overall performance improvement.
- Clinical Research Progress: Gossamer Bio discussed positive topline results from its PROSERA Phase 3 study in pulmonary arterial hypertension, potentially laying the groundwork for future market introduction and boosting investor confidence in its R&D pipeline.
- Market Reaction: Although the EPS fell short of expectations, the robust revenue growth and positive clinical study results may enhance the market's overall perception of Gossamer Bio, potentially driving a rebound in stock price.
See More
Gossamer Bio Reports 2025 Financial Results and Strategic Update
- PROSERA Study Results: Gossamer Bio's PROSERA Phase 3 study revealed that seralutinib improved six-minute walk distance (6MWD) by approximately +13.3 meters at 24 weeks, failing to meet the pre-specified statistical threshold, although a +20.0 meters improvement was observed in the high-risk subgroup, indicating potential efficacy in severe patients.
- SERANATA Study Enrollment Paused: The company has paused enrollment in the SERANATA study for PH-ILD to evaluate the implications of PROSERA results and engage with the FDA on potential regulatory pathways, reflecting a cautious approach to clinical trial design.
- Workforce Reduction and Cost Control: To better align resources with near-term priorities, the company implemented a reduction in force and other cost-containment measures aimed at optimizing capital allocation and focusing on regulatory and strategic planning for seralutinib.
- Financial Overview: As of December 31, 2025, the company reported cash and cash equivalents of $137 million, expected to fund operations and capital expenditures into Q1 2027, despite a net loss of $170.4 million, highlighting financial pressure alongside ongoing R&D investments.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Gossamer Bio Performance Review: On February 23, Gossamer Bio announced topline results from the PROSERA Phase 3 study, indicating the drug's activity in pulmonary arterial hypertension patients despite narrowly missing the statistical threshold, resulting in a 76% stock drop over the past month, with an RSI of 26.3 indicating oversold conditions.
- Brainsway Clinical Data: On March 4, Brainsway disclosed new clinical data showing a significantly faster, non-invasive treatment for depression, with a 52-week low of $3.92 and an RSI of 19.1, suggesting its stock is also oversold.
- Definitive Healthcare Earnings: Definitive Healthcare posted inline Q4 earnings on February 26, with CEO Kevin Coop highlighting progress across strategic pillars, despite a 38% stock drop in the past month and an RSI of 28.1, indicating potential for a rebound.
- Market Trend Analysis: Benzinga Pro signals indicate potential breakout opportunities for both Gossamer Bio and Definitive Healthcare, with respective stock gains of 23.4% and 5.2% on Wednesday, providing investors with signals to explore opportunities in oversold healthcare stocks.
See More
Gossamer Bio Under Investigation as Stock Plummets 80%
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Gossamer Bio, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to significant legal risks.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, directly impacting investor confidence and raising concerns about the company's drug pipeline.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting extreme market pessimism regarding the company's future prospects and financial health.
- Potential Legal Consequences: The investigation could lead to a class action lawsuit against Gossamer, and if found guilty of fraud, the company may face severe financial repercussions and reputational damage, prompting investors to closely monitor developments.
See More
Cantor Fitzgerald Downgrades Gossamer Bio Amid Regulatory Uncertainty
- Rating Downgrade: Cantor Fitzgerald has downgraded Gossamer Bio from overweight to neutral due to uncertainty surrounding the regulatory path for seralutinib as a treatment for pulmonary arterial hypertension, indicating a decline in market confidence regarding the drug's future prospects.
- Clinical Trial Disappointment: The topline results from the February PROSERA phase 3 study failed to meet statistical significance, leading analysts to adopt a cautious stance on Gossamer's commercialization potential, although they still acknowledge some compelling data indicating a solid signal for the drug.
- FDA Meeting Request: Gossamer has requested a Type C meeting with the US FDA, expected to take place in June, which should provide clearer guidance on seralutinib's path forward, with potential clarity anticipated in July.
- Market Sentiment: Analyst Olivia Brayer Saunders noted that while Gossamer possesses some compelling data, the lack of strong conviction regarding the commercialization path may impact investor sentiment towards the company's long-term outlook.
See More
Gossamer Bio Under Investigation as Stock Plummets 80.14%
- Investigation Launched: Pomerantz LLP is investigating Gossamer Bio, Inc. for potential securities fraud or unlawful business practices, highlighting serious concerns among investors regarding corporate governance.
- Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, leading to a significant drop in market confidence.
- Stock Plunge: Following the trial failure announcement, Gossamer's stock price fell by $1.71, a staggering 80.14% decline, closing at $0.423 per share, reflecting investors' pessimism about the company's future prospects.
- Legal Implications: The investigation may result in Gossamer facing class action lawsuits, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, further exacerbating the legal risks the company faces.
See More
Gossamer Bio Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Report: Gossamer Bio's Q4 GAAP EPS of -$0.21 missed expectations by $0.02, indicating ongoing challenges in achieving profitability despite revenue growth.
- Revenue Surge: The company reported Q4 revenue of $13.8 million, a 47.8% year-over-year increase, exceeding market expectations by $6.28 million, reflecting strong product demand and overall performance improvement.
- Clinical Research Progress: Gossamer Bio discussed positive topline results from its PROSERA Phase 3 study in pulmonary arterial hypertension, potentially laying the groundwork for future market introduction and boosting investor confidence in its R&D pipeline.
- Market Reaction: Although the EPS fell short of expectations, the robust revenue growth and positive clinical study results may enhance the market's overall perception of Gossamer Bio, potentially driving a rebound in stock price.
See More
Gossamer Bio Reports 2025 Financial Results and Strategic Update
- PROSERA Study Results: Gossamer Bio's PROSERA Phase 3 study revealed that seralutinib improved six-minute walk distance (6MWD) by approximately +13.3 meters at 24 weeks, failing to meet the pre-specified statistical threshold, although a +20.0 meters improvement was observed in the high-risk subgroup, indicating potential efficacy in severe patients.
- SERANATA Study Enrollment Paused: The company has paused enrollment in the SERANATA study for PH-ILD to evaluate the implications of PROSERA results and engage with the FDA on potential regulatory pathways, reflecting a cautious approach to clinical trial design.
- Workforce Reduction and Cost Control: To better align resources with near-term priorities, the company implemented a reduction in force and other cost-containment measures aimed at optimizing capital allocation and focusing on regulatory and strategic planning for seralutinib.
- Financial Overview: As of December 31, 2025, the company reported cash and cash equivalents of $137 million, expected to fund operations and capital expenditures into Q1 2027, despite a net loss of $170.4 million, highlighting financial pressure alongside ongoing R&D investments.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Gossamer Bio Performance Review: On February 23, Gossamer Bio announced topline results from the PROSERA Phase 3 study, indicating the drug's activity in pulmonary arterial hypertension patients despite narrowly missing the statistical threshold, resulting in a 76% stock drop over the past month, with an RSI of 26.3 indicating oversold conditions.
- Brainsway Clinical Data: On March 4, Brainsway disclosed new clinical data showing a significantly faster, non-invasive treatment for depression, with a 52-week low of $3.92 and an RSI of 19.1, suggesting its stock is also oversold.
- Definitive Healthcare Earnings: Definitive Healthcare posted inline Q4 earnings on February 26, with CEO Kevin Coop highlighting progress across strategic pillars, despite a 38% stock drop in the past month and an RSI of 28.1, indicating potential for a rebound.
- Market Trend Analysis: Benzinga Pro signals indicate potential breakout opportunities for both Gossamer Bio and Definitive Healthcare, with respective stock gains of 23.4% and 5.2% on Wednesday, providing investors with signals to explore opportunities in oversold healthcare stocks.
See More
